Drug Type Universal CAR-T |
Synonyms 4SCAR7U |
Target |
Action modulators |
Mechanism CD7 modulators(T-cell antigen CD7 modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 1 | China | 31 Oct 2023 | |
CD7 positive Hematologic Neoplasms | Phase 1 | China | 31 Oct 2023 | |
CD7 Positive Neoplasms | Phase 1 | China | 31 Oct 2023 | |
NK-cell lymphoma | Phase 1 | China | 31 Oct 2023 | |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | China | 31 Oct 2023 | |
T-cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | China | 31 Oct 2023 |